Ascendis Pharma A/S (NASDAQ:ASND) Given Consensus Rating of “Moderate Buy” by Analysts

Ascendis Pharma A/S (NASDAQ:ASND) has been assigned a consensus rating of “Moderate Buy” from the fourteen research firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $192.07.

A number of analysts have weighed in on ASND shares. Bank of America boosted their target price on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. Oppenheimer decreased their target price on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research report on Friday, November 15th. TD Cowen lowered their price objective on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research report on Friday, November 15th. JPMorgan Chase & Co. lowered their price objective on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating for the company in a research note on Wednesday, October 23rd. Finally, Wedbush reaffirmed an “outperform” rating and set a $181.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, November 15th.

Ascendis Pharma A/S Stock Down 2.1 %

NASDAQ:ASND opened at $134.43 on Thursday. The firm has a market capitalization of $8.16 billion, a PE ratio of -16.64 and a beta of 0.65. The stock’s 50-day simple moving average is $132.30 and its 200 day simple moving average is $133.59. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $161.00.

Institutional Trading of Ascendis Pharma A/S

Institutional investors and hedge funds have recently modified their holdings of the business. Rhumbline Advisers raised its holdings in shares of Ascendis Pharma A/S by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 143 shares during the period. Headlands Technologies LLC bought a new stake in Ascendis Pharma A/S during the second quarter worth about $864,000. First Turn Management LLC lifted its position in Ascendis Pharma A/S by 23.1% in the 2nd quarter. First Turn Management LLC now owns 186,581 shares of the biotechnology company’s stock worth $25,446,000 after buying an additional 34,994 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its holdings in shares of Ascendis Pharma A/S by 42.0% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 6,927 shares of the biotechnology company’s stock worth $945,000 after acquiring an additional 2,048 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its position in Ascendis Pharma A/S by 5.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 1,711,015 shares of the biotechnology company’s stock valued at $233,348,000 after buying an additional 93,185 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.